Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Response Comparison Between Alternate-Day and Daily Lenalidomide Maintenance in Transplant-Ineligible Multiple Myeloma Patients
TCTR20250625007Phase 4Not yet recruiting
- Sponsor
- Mahidol University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lenalidomide in multiple myeloma (MM), sponsored by Mahidol University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on TCTR20250625007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250625007.